“Diabetes doesn’t have a cure either - it doesn’t mean you can’t have very meaningful treatments for patients.” John Sims told reporters Monday at the Alzheimer’s Association International Conference in Amsterdam. “Finally there’s some hope, right, that we can talk about,” Lilly’s Dr.
If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease - after the recently approved Leqembi from Japanese drugmaker Eisai. is seeking Food and Drug Administration approval of donanemab. WASHINGTON (AP) - Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening - by about four to seven months, researchers reported Monday.Įli Lilly and Co.
